A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

NCT01558271 on ClinicalTrials.gov · last registry update 2015-05-22

Finished October 2013, after enrolling 492 people. Primary outcome, as filed: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 492
Started: 2012-03
Primary completion: 2013-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.